Payload Information
General Information of This Payload
| Payload ID | PAY0FNGSJ |
|||||
|---|---|---|---|---|---|---|
| Name | Mitomycin C |
|||||
| Synonyms |
Mitomycin C; Mitomycin; 50-07-7; Ametycine; Mutamycin; Mitomycin-C; Mitocin-C; Mytozytrex; Ametycin; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitamycin; Mitosol; MMC; NSC-26980; Muamycin; 7-Amino-9alpha-methoxymitosane; Mitomycyna C; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycins; Mitomycin (TN); C15H18N4O5; NSC 26980; Mitomicina; Mitomycine; Mitomycine [INN-French]; Mitomycinum [INN-Latin]; NCI-C04706; Mitomicina [INN-Spanish]; RCRA waste number U010; NSC26980; Muamycin (TN); CCRIS 414; Mitomycin [USAN:INN:BAN]; HSDB 3239; Mitomycin (USP/INN); EINECS 200-008-6; Mitomycin C, Streptomyces caespitosus; RCRA waste no. U010; UNII-50SG953SK6; AI3-26199; DTXSID2020898; CHEBI:27504; UGN-101; UGN-102; Mitomycin [USAN:USP:INN:BAN]; 50SG953SK6; Mitomycin C, Streptomyces caespitosus, Carrier-Free; [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-dien-8-yl]methyl carbamate; 6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester); Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))-; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-; DTXCID00898; CAS-50-07-7; ((1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl carbamate; [(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; 1404-00-8; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-, carbamate (ester); Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-; Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aalpha,8beta,8aalpha,8balpha)]-; MLS002702984; (amino-methoxy-methyl-dioxo-[?]yl)methyl carbamate; 7-Amino-9.alpha.-methoxymitosane; Mitonco; Mitoplus; MitoExtra; mitomycin-; NCGC00095258-01; [(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; AZIRINO(2',3':3,4)PYRROLO(1,2-A)INDOLE-4,7-DIONE, 6-AMINO-8-(((AMINOCARBONYL)OXY)METHYL)-1,1A,2,8,8A,8B-HEXAHYDRO-8A-METHOXY-5-METHYL-, (1AS-(1A.ALPHA.,8.BETA.,8A.ALPHA.,8B.ALPHA.))-; Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-; Jelmyto (TN); MFCD00078109; JELMYTO; Mitomycin C- Bio-X; MITOMYCIN [INN]; Mitomycin C (JP17); MITOMYCIN [HSDB]; MITOMYCIN [USAN]; MITOMYCIN [VANDF]; MITOMYCIN C [MI]; CHEMBL105; D0NZ1U; D0Y0GH; MITOMYCIN [MART.]; MITOMYCIN C [JAN]; MITOMYCIN [USP-RS]; MITOMYCIN [WHO-DD]; MITOMYCIN C [IARC]; SCHEMBL3760; CBiol_001927; BSPBio_001267; KBioGR_000607; KBioSS_000607; Mitomycin [USAN:BAN:INN]; Mitomycin C (4% in NaCl); MLS001332654; Mitozytrex (TN) (Supergene); 50-07-7 (non-salt); AMETYCIN pound notmitomycin C; GTPL7089; MITOMYCIN [ORANGE BOOK]; MITOMYCIN [EP MONOGRAPH]; UNII-V03E10691T; KBio2_000607; KBio2_003175; KBio2_005743; KBio3_001073; KBio3_001074; EX-A501; MITOMYCIN [USP MONOGRAPH]; NWIBSHFKIJFRCO-WUDYKRTCSA-N; BCPP000410; Bio1_000213; Bio1_000702; Bio1_001191; Bio2_000464; Bio2_000944; HMS1362O09; HMS1792O09; HMS1990O09; HMS2089F16; HMS3403O09; AMY10316; Tox21_111493; AC-918; BDBM50428658; GR-311; HB4458; LS-136; s8146; AKOS015895703; Tox21_111493_1; BCP9000285; CCG-208564; CS-0564; DB00305; KS-5148; IDI1_002219; SMP1_000307; Mitomycin 100 microg/mL in Acetonitrile; NCGC00163468-02; NCGC00163468-03; NCGC00163468-05; NCGC00163468-06; [1aS-(1aalpha,8beta,8aalpha,8balpha)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; BM164668; HY-13316; SMR000058401; BCP0726000181; LS-173087; M2320; C06681; D00208; D91590; AB00918689-03; AB00918689-04; EN300-7405455; Mitomycin C, Antibiotic for Culture Media Use Only; Q-201410; BRD-K59670716-001-02-6; BRD-K59670716-001-06-7; Q19856779; WLN: T D3 B556 BN EM JV MVTTT&J GO1 H1OVZ KZ L1; Mitomycin C from Streptomyces caespitosus, >=970 mug/mg (USP XXIV); Mitomycin C from Streptomyces caespitosus, powder, BioReagent, suitable for cell culture; Mitomycin C from Streptomyces caespitosus, powder, contains NaCl as solubilizer; (1ar)-6-amino-8-(((aminoc arbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; (1ar)-6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; [1aR-(1aalpha,8beta,8aalpha,8balpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-alpha]indole-4,7-dione; [1aS-(1a?,8?,8a?,8b?)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino[2',3':3, 4]pyrrolo[1,2-a]indole-4,7-dione, carbamate (ester); 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, carbamate (ester); 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl, [1aS-(1aalpha,8beta,8aalpha,8balpha)]-azirino[2',3':3,4]pyrrol o[1,2a]indole-4,7-dione; 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl, [1aS-(1aalpha,8beta,8aalpha,8balpha)]-azirino[2',3':3,4]pyrrolo[1,2a]indole-4,7-dione; Azirino [2', 3': 3,4] pirrolo [1,2-a] indol-4,7-diona, 6-amino-8-[[(aminocarbonil) oxi] metil]-1,1 a, 2, 8,8 a, 8b-hexahidro-8a-metoxi-5-metil-, (1as, 8S, 8aR, 8BS)-; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))- (9CI); Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a, 2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-; Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl -, [1aS-(1aalpha,8beta,8aalpha,8balpha)]-; AZIRINO[2',3':3,4]PYRROLO[1,2-A]INDOLE-4,7-DIONE, 6-AMINO-8-[[(AMINOCARBONYL)OXY]METHYL]-1,1A,2,8,8A,8B-HEXAHYDRO-8A-METHOXY-5-METHYL-, [1AS-(1A.APHA.,8.BETA.,8A.ALPHA.,8B.ALPHA.)]-; Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-5-methyl-, carbamate (ester); Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b- hexahydro-8a-methoxy-5-methyl-, [1aR-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-; Azirino[2,3:3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-; Mitomycin C from Streptomyces caespitosus, >=98% (HPLC), potency: >=970 mug per mg (USP XXIV), gamma-irradiated, suitable for cell culture
Click to Show/Hide
|
|||||
| Target(s) | Human Deoxyribonucleic acid (hDNA) | |||||
| Structure |
|
|||||
| Formula | C15H18N4O5 |
|||||
| Isosmiles | CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
|
|||||
| InChIKey |
NWIBSHFKIJFRCO-WUDYKRTCSA-N
|
|||||
| IUPAC Name |
[(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
|
|||||
| Pharmaceutical Properties | Molecule Weight |
334.33 |
Polar area |
147 |
||
Complexity |
757 |
xlogp Value |
-0.4 |
|||
Heavy Count |
24 |
Rot Bonds |
4 |
|||
Hbond acc |
8 |
Hbond Donor |
3 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
HeLa cells
|
Endocervical adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
HCT 116 cells
|
Colon carcinoma
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
Hep 3B2.1-7 cells
|
Childhood hepatocellular carcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[3] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[4] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
Lu-99 cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
HA59T/VGH cells
|
Hepatocellular carcinoma
|
[3] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug/mL |
Hepa-1 cells
|
Hepatocellular carcinoma of the mouse
|
[4] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.015 | ug/mL |
A-549 cells
|
Lung adenocarcinoma
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.015 | ug/mL |
HCT 116 cells
|
Colon carcinoma
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | ug/mL |
A-549 cells
|
Lung adenocarcinoma
|
[5] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | ug/mL |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | ug/mL |
L1210 cells
|
Lymphoblastic leukemia
|
[5] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | ug/mL |
P388 cells
|
Lymphoma
|
[6] | |
| Half Maximal Effective Concentration (EC50) | 0.04 | ug/mL |
Hepa-1 cells
|
Hepatocellular carcinoma of the mouse
|
[7] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.05 | ug/mL |
Daoy cells
|
Medulloblastoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.06 | ug/mL |
HeLa cells
|
Endocervical adenocarcinoma
|
[8] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.06 | ug/mL |
P388 cells
|
Lymphoma
|
[9] | |
| Half Maximal Effective Concentration (EC50) | 0.07 | ug/mL |
HEp-2 cells
|
Laryngeal carcinoma
|
[10] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.08 | ug/mL |
A-549 cells
|
Lung adenocarcinoma
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.08 | ug/mL |
A-549 cells
|
Lung adenocarcinoma
|
[11] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.08 | ug/mL |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[8] | |
| Half Maximal Effective Concentration (EC50) | 0.08 | ug/mL |
Daoy cells
|
Medulloblastoma
|
[12] | |
| Half Maximal Effective Concentration (EC50) | 0.09 | ug/mL |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[12] | |
| Half Maximal Effective Concentration (EC50) | 0.1 | ug/mL |
DLD-1 cells
|
Colon adenocarcinoma
|
[13] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.1 | ug/mL |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[11] | |
| Half Maximal Effective Concentration (EC50) | 0.1 | ug/mL |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[14] | |
| Half Maximal Effective Concentration (EC50) | 0.1 | ug/mL |
Daoy cells
|
Medulloblastoma
|
[14] | |
| Half Maximal Effective Concentration (EC50) | 0.1 | ug/mL |
HEp-2 cells
|
Laryngeal carcinoma
|
[14] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.1 | ug/mL |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
[15] | |
| Half Maximal Effective Concentration (EC50) | 0.12 | ug/mL |
HEp-2 cells
|
Laryngeal carcinoma
|
[12] | |
| Half Maximal Effective Concentration (EC50) | 0.13 | ug/mL |
HeLa cells
|
Endocervical adenocarcinoma
|
[12] | |
| Half Maximal Effective Concentration (EC50) | 0.13 | ug/mL |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[13] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.14 | ug/mL |
Hep-G2 cells
|
Hepatoblastoma
|
[16] | |
| Half Maximal Effective Concentration (EC50) | 0.14 | ug/mL |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[10] | |
| Half Maximal Effective Concentration (EC50) | 0.14 | ug/mL |
Daoy cells
|
Medulloblastoma
|
[10] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.15 | ug/mL |
HT-1080 cells (FAP expression)
|
Fibrosarcoma
|
[16] | |
| Half Maximal Effective Concentration (EC50) | 0.15 | ug/mL |
WiDr cells
|
Colon adenocarcinoma
|
[10] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.15 | ug/mL |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[11] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.15 | ug/mL |
P388 cells
|
Lymphoma
|
[17] | |
| Half Maximal Effective Concentration (EC50) | 0.2 | ug/mL |
HeLa cells
|
Endocervical adenocarcinoma
|
[14] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.24 | ug/mL |
SW900 cells
|
Lung squamous cell carcinoma
|
[2] | |
| Half Maximal Effective Concentration (EC50) | 0.35 | ug/mL |
WiDr cells
|
Colon adenocarcinoma
|
[7] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.36 | ug/mL |
Hep-G2 cells
|
Hepatoblastoma
|
[11] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.45 | ug/mL |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[11] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.47 | ug/mL |
A-549 cells
|
Lung adenocarcinoma
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.54 | ug/mL |
A-549 cells
|
Lung adenocarcinoma
|
[16] | |
| Half Maximal Effective Concentration (EC50) | 0.56 | ug/mL |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[7] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.97 | ug/mL |
U-87MG ATCC cells
|
Glioblastoma
|
[11] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | ug/mL |
B16-F10 cells
|
Mouse melanoma
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.55 | ug/mL |
PC-3 cells
|
Prostate carcinoma
|
[11] | |
| Half Maximal Effective Concentration (EC50) | 1.7 | mgkg <sup>-1</sup> |
CCRF S-180 cells
|
Fibroblast sarcoma
|
[18] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.75 | ug/mL |
RKO cells
|
Colon carcinoma
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 13.1 | ug/mL |
Farage cells
|
Normal
|
[20] | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | ug/mL |
CCD 19Lu cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.32 | ug/mL |
SNU-1 cells
|
Gastric adenocarcinoma
|
[9] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.33 | ug/mL |
Bcap37 cells
|
Breast carcinoma
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.44 | ug/mL |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | ug/mL |
Sf9 cells
|
Normal
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | ug/mL |
C6/36 cells
|
Normal
|
[21] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.35 | ug/mL |
K-562 cells
|
Chronic myelogenous leukemia
|
[19] | |
| Half Maximal Inhibitory Concentration (IC50) | 3.6 | ug/mL |
B16 cells
|
Melanoma
|
[2] | |
| Half Maximal Effective Concentration (EC50) | 4.4 | ug/mL |
CCRF S-180 cells
|
Fibroblast sarcoma
|
[22] | |
| Half Maximal Inhibitory Concentration (IC50) | 8.1 | ug/mL |
SW1271 cells
|
Lung small cell carcinoma
|
[2] | |
| Half Maximal Inhibitory Concentration (IC50) | 0.02213 | nM |
NTERA-2-cl-D1 cells
|
Teratocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.03248 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.119 | nM |
J82 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1283 | nM |
697 cells
|
Childhood B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1486 | nM |
KYSE-510 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1513 | nM |
NCI-H2170 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1673 | nM |
BE-13 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.2492 | nM |
LC-2-ad cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.3076 | nM |
IMR-5 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.31 | nM |
EW-16 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.638 | nM |
MC-IXC cells
|
Askin tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.676 | nM |
SW872 cells
|
Liposarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7963 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[23] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.066 | nM |
NALM-6 cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.08 | nM |
CHO-AA8 cells
|
Normal
|
[24] | |
| Half Maximal Inhibitory Concentration (IC50) | 1.555 | nM |
ES4 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.636 | nM |
KE-37 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.684 | nM |
IST-MEL1 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.712 | nM |
ES8 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.732 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.759 | nM |
639-V cells
|
Ureter urothelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.886 | nM |
OCI-AML-2 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
WiDr cells
|
Colon adenocarcinoma
|
[25] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[26] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
THP-1 cells
|
Childhood acute monocytic leukemia
|
[27] | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[25] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 100 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[28] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Cancer
|
Undisclosed | [29] |
| Half Maximal Inhibitory Concentration (IC50) | 100.6 | nM |
M059J cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
Ca-Ski cells
|
Cervical squamous cell carcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CNE-2 cells
|
Normal
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 1005.45 | nM |
SW1417 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 101.83 | nM |
UM-UC-3 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1010.24 | nM |
NCC-IT cells
|
Testicular embryonal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1011.63 | nM |
MMAC-SF cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1012.47 | nM |
Lu-65 cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1014.28 | nM |
NCI-H1623 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1015.02 | nM |
HCT 116 cells
|
Colon carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1016.25 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1019.8 | nM |
CA46 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 102.42 | nM |
ES5 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 102.84 | nM |
KYSE-270 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 102.98 | nM |
OCUB-M cells
|
Breast carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1020.94 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 103.51 | nM |
C-4-II cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 103.78 | nM |
BOKU cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1031.57 | nM |
RERF-LC-MS cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1033.04 | nM |
DJM-1 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1033.74 | nM |
EM-2 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10380.73 | nM |
MFM-223 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 104 | nM |
8-MG-BA cells
|
Glioblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 104.23 | nM |
DMS-273 cells
|
Small cell lung carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 104.73 | nM |
SW982 cells
|
Biphasic synovial sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 105.8 | nM |
AGS cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 105.97 | nM |
IGROV-1 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1057.54 | nM |
HCC1395 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 106.06 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 106.63 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 106.7 | nM |
HOS cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1063771.62 | nM |
SCH cells
|
Gastric choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1066.4 | nM |
HCC1143 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1073.8 | nM |
HH cells
|
T-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1079.17 | nM |
MDA-MB-453 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1079.2 | nM |
COLO 320HSR cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 108.1 | nM |
HuP-T4 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 108.24 | nM |
ETK-1 cells
|
Cholangiocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 108.63 | nM |
IA-LM cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1083.64 | nM |
KM12 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1092.39 | nM |
KNS-42 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1097.15 | nM |
HPAF-II cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1099.01 | nM |
HOP-18 cells
|
Non-small cell lung adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 11.48 | nM |
SF-295 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 110.25 | nM |
MRK-nu-1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 110.4 | nM |
SUP-T1 cells
|
T lymphoblastic lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1100 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[33] | |
| Half Maximal Inhibitory Concentration (IC50) | 11030 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[34] | |
| Half Maximal Inhibitory Concentration (IC50) | 11030 | nM |
HCT 116 cells
|
Colon carcinoma
|
[34] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1106.62 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1124.6 | nM |
RXF 631 cells
|
Renal carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 112568.06 | nM |
SW684 cells
|
Fibrosarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1127.2 | nM |
XF498 cells
|
Glioma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1127.87 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1130 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[35] | |
| Half Maximal Inhibitory Concentration (IC50) | 1131.22 | nM |
EFO-27 cells
|
Ovarian mucinous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 115.1 | nM |
A2058 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1157.78 | nM |
L-428 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 116.4 | nM |
Capan-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 116.8 | nM |
NCI-H1355 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 117.76 | nM |
NCI-H1618 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1178.08 | nM |
LS-513 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 119.58 | nM |
QIMR-WIL cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11969 | nM |
NCI-H596 cells
|
Lung adenosquamous carcinoma
|
[36] | |
| Half Maximal Inhibitory Concentration (IC50) | 12.14 | nM |
EW-7 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.44 | nM |
H4 cells
|
Neuroglioma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 120 | nM |
Cancer cells
|
Cancer
|
Undisclosed | [29] |
| Half Maximal Inhibitory Concentration (IC50) | 120.17 | nM |
HCC1599 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1203.71 | nM |
NB12 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1206.61 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1207.81 | nM |
UACC-257 cells
|
Melanoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 121.34 | nM |
GR-ST cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 121.62 | nM |
SR cells
|
Leukemia
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1211.41 | nM |
TGBC1TKB cells
|
Gallbladder undifferentiated carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1218.41 | nM |
LU-139 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1220.94 | nM |
Raji cells
|
EBV-related Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1228.41 | nM |
IPC-298 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 123.93 | nM |
G-361 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1232.91 | nM |
NCI-H838 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1238.47 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1239.59 | nM |
LC4-1 cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12422.72 | nM |
NCI-H446 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 125.29 | nM |
RKO cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 126.26 | nM |
NCI-H1437 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1263.32 | nM |
MN-60 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 127.02 | nM |
SF539 cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 127.91 | nM |
ACN cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1273.72 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1276.67 | nM |
BL-70 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 128.29 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 128.73 | nM |
U-251MG cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 129.14 | nM |
KALS-1 cells
|
Glioblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 129.42 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1291.22 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1297.18 | nM |
KM-20L2 cells
|
Colon carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
WiDr cells
|
Colon adenocarcinoma
|
[37] | |
| Half Maximal Inhibitory Concentration (IC50) | 13.19 | nM |
LB2241-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.3 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 13.46 | nM |
SR cells
|
Leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.6 | nM |
LB1047-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.9 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.92 | nM |
ESS-1 cells
|
Endometrioid stromal sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.96 | nM |
NCI-H2122 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 130.45 | nM |
KM-H2 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1309.78 | nM |
MLMA cells
|
Hairy cell leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 131.22 | nM |
UACC-62 cells
|
Melanoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 131.56 | nM |
SJSA-1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1317.77 | nM |
RPMI-8866 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 132.24 | nM |
TE-5 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13200 | nM |
Farage cells
|
Normal
|
[38] | |
| Half Maximal Inhibitory Concentration (IC50) | 13327.4 | nM |
RO82-W-1 cells
|
Thyroid gland follicular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1337.6 | nM |
M14 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 134.17 | nM |
SNG-M cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 134.54 | nM |
HCC1806 cells
|
Breast squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1349.36 | nM |
RCC10RGB cells
|
Renal cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1358.31 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 136.85 | nM |
NCI-H1734 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1374.23 | nM |
SK-MEL-24 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1378.3 | nM |
SHP-77 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 138.72 | nM |
LCLC-97TM1 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1381.25 | nM |
EFE-184 cells
|
Endometrial carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1386.76 | nM |
P388/ADR cells
|
Lymphoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 139.13 | nM |
NH-12 cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 139.42 | nM |
A375 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1390.89 | nM |
GI-ME-N cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.01 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.33 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1400 | nM |
PC-3 cells
|
Prostate carcinoma
|
[39] | |
| Half Maximal Inhibitory Concentration (IC50) | 1400 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[33] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1400 | nM |
HEC-6 cells
|
Endometrial endometrioid adenocarcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 1400 | nM |
PC-3 cells
|
Prostate carcinoma
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 1405.65 | nM |
SF-126 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1406.49 | nM |
SAOS-2 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 141.21 | nM |
SNU-5 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1416.51 | nM |
Karpas-299 cells/Karpas BVR cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1416.64 | nM |
MC116 cells
|
B-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 142.64 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 142.83 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1427.84 | nM |
NCI-H1563 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 144.07 | nM |
22RV1 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 144.68 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 144.71 | nM |
BB65-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 144.94 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1444.61 | nM |
COLO-824 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1446.2 | nM |
IST-SL1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1460.1 | nM |
HDLM-2 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1460.85 | nM |
NCI-H1573 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 147.91 | nM |
ACHN cells
|
Renal adenocarcinoma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 148.25 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 149.34 | nM |
K052 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 149.96 | nM |
KU812 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14913.25 | nM |
EC-GI-10 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1497.85 | nM |
NCI-H2171 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.73 | nM |
HAL-01 cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.8 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[23] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[41] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[42] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
PC-3 cells
|
Prostate carcinoma
|
[43] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
PC-3 cells
|
Prostate carcinoma
|
[44] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
PC-3 cells
|
Prostate carcinoma
|
[45] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[46] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
HEp-2 cells
|
Laryngeal carcinoma
|
[43] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
PC-3 cells
|
Prostate carcinoma
|
[47] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
PC-3 cells
|
Prostate carcinoma
|
[48] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
THP-1 cells
|
Childhood acute monocytic leukemia
|
[47] | |
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM |
THP-1 cells
|
Childhood acute monocytic leukemia
|
[48] | |
| Half Maximal Inhibitory Concentration (IC50) | 1502.27 | nM |
NOS-1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1502.64 | nM |
COLO-792 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 151.41 | nM |
NOMO-1 cells
|
Acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1521.81 | nM |
SNU-423 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1528.34 | nM |
C32 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1531.03 | nM |
KOSC-2 cells
|
Floor of mouth squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1534.44 | nM |
NCI-H64 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1536.59 | nM |
HT cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1537.7 | nM |
NCI-H596 cells
|
Lung adenosquamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1544.25 | nM |
NCI-H720 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 155.57 | nM |
Ca9-22 cells
|
Gingival squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 155.75 | nM |
8305C cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15525 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[36] | |
| Half Maximal Inhibitory Concentration (IC50) | 156.24 | nM |
SNU-1 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 156.51 | nM |
HC-1 cells
|
Hairy cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1565.66 | nM |
UACC-257 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 157.55 | nM |
SW 962 cells
|
Vulva lymphoid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1573.68 | nM |
EVSA-T cells
|
Breast carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 158.49 | nM |
DU145 cells
|
Prostate carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1594.46 | nM |
KNS-81-FD cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.26 | nM |
MHH-ES-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.95 | nM |
NUGC-3 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 160.13 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 160.83 | nM |
DMS-273 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 160.91 | nM |
MC/CAR cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1602.76 | nM |
TE-441-T cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1602.91 | nM |
U-698-M cells
|
Lymphoblastic lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 161.72 | nM |
Caov-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1613.17 | nM |
COR-L105 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 162.39 | nM |
EoL-1 cells
|
Chronic eosinophilic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1624.13 | nM |
KMOE-2 cells
|
Erythroleukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1648.16 | nM |
SK-MEL-2 cells (MEK inhibitor-resistant)
|
Melanoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 165.04 | nM |
MKN45 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 165.38 | nM |
TF-1 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 165.58 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1650.78 | nM |
KY821 cells
|
Acute myelomonocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 166.06 | nM |
HMV-2 cells
|
Vaginal melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 166.53 | nM |
SK-NEP-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 166.72 | nM |
SF-295 cells
|
Glioblastoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 167.16 | nM |
Panc 03.27 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 167.55 | nM |
RPMI-7951 cells
|
Malignant melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16710 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[34] | |
| Half Maximal Inhibitory Concentration (IC50) | 1674.2 | nM |
SJRH30 cells
|
Alveolar rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1678.82 | nM |
NCI-H69 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 168.65 | nM |
NCI-H520 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1680 | nM |
SPC-A1 cells
|
Endocervical adenocarcinoma
|
[49] | |
| Half Maximal Inhibitory Concentration (IC50) | 16830.61 | nM |
UACC-812 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 169.45 | nM |
NCI-H522 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16970 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[50] | |
| Half Maximal Inhibitory Concentration (IC50) | 1699.23 | nM |
RT-4 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.13 | nM |
RPMI-8402 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.39 | nM |
ATN-1 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.6 | nM |
NCI-H441 cells
|
Lung papillary adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.68 | nM |
LB996-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.83 | nM |
CAL-148 cells
|
Breast carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 17.95 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 170 | nM |
DU145 cells
|
Prostate carcinoma
|
[51] | |
| Half Maximal Inhibitory Concentration (IC50) | 170 | nM |
DU145 cells
|
Prostate carcinoma
|
[52] | |
| Half Maximal Inhibitory Concentration (IC50) | 170.26 | nM |
Detroit 562 cells
|
Pharyngeal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 170.86 | nM |
SF268 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1700 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[39] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1700 | nM |
MKN-74 cells
|
Stomach adenocarcinoma
|
[28] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1702.16 | nM |
MDA-N cells
|
Breast carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1720.01 | nM |
LS-123 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 173.34 | nM |
T84 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1737.8 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1740.29 | nM |
BHT-101 cells
|
Anaplastic thyroid carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1745.82 | nM |
BT-549 cells
|
Breast ductal carcinoma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1749.85 | nM |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 175.06 | nM |
NB69 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 175.54 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 177.98 | nM |
RT-112 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1783.98 | nM |
K5 cells
|
Thyroid gland papillary carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1790.73 | nM |
SK-N-AS cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.67 | nM |
CTV-1 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 180 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[53] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 180 | nM |
Cancer cells
|
Cancer
|
Undisclosed | [29] |
| Half Maximal Inhibitory Concentration (IC50) | 180 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[54] | |
| Half Maximal Inhibitory Concentration (IC50) | 180 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[55] | |
| Half Maximal Inhibitory Concentration (IC50) | 180.37 | nM |
DoTc2-4510 cells
|
Cervix uteri
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1800 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[56] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1800 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 1800 | nM |
DU145 cells
|
Prostate carcinoma
|
[40] | |
| Half Maximal Inhibitory Concentration (IC50) | 1800 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[57] | |
| Half Maximal Inhibitory Concentration (IC50) | 1801.52 | nM |
NCI-H322M cells
|
Minimally invasive lung adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 181.13 | nM |
P388 cells
|
Lymphoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1814.82 | nM |
NCI-H1793 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1841.48 | nM |
CAL-54 cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 185.8 | nM |
J-RT3-T3-5 cells
|
T acute lymphoblastic leukemi
|
||
| Half Maximal Inhibitory Concentration (IC50) | 186.61 | nM |
NB1 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 186.77 | nM |
NEC8 cells
|
Testicular embryonal carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 1866.38 | nM |
UO-31 cells
|
Renal carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 1870 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[50] | |
| Half Maximal Inhibitory Concentration (IC50) | 1888.15 | nM |
SK-MEL-1 cells
|
Metastatic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 189.67 | nM |
TUR cells
|
Acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 189.83 | nM |
TE-12 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1893.4 | nM |
SiHa cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18973.1 | nM |
SK-MEL-28 cells (BRAF inhibitor resistant)
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1898.46 | nM |
RD cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 190 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[35] | |
| Half Maximal Inhibitory Concentration (IC50) | 1910.33 | nM |
ChaGo-K-1 cells
|
Bronchogenic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1914 | nM |
SNU-C1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 192.04 | nM |
WSU-NHL cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 192.55 | nM |
MHH-NB-11 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1927.42 | nM |
NCI-H1436 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 193.36 | nM |
SW48 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1936.58 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 194.31 | nM |
C3A cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 195.75 | nM |
RPMI-2650 cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1954.57 | nM |
HT55 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1978.69 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 198.77 | nM |
VMRC-RCZ cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1988.12 | nM |
NCI-H2052 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
[58] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.217 | nM |
SK-LU-1 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.548 | nM |
Reh cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.554 | nM |
PSN1 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.589 | nM |
SBC-5 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.928 | nM |
HT-3 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.2 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
[25] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[25] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 200 | nM |
HCT 116 cells
|
Colon carcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
SK-OV-3 cells (FZD7 overexpression)
|
Ovarian serous cystadenocarcinoma
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[60] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[27] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
PC-3 cells
|
Prostate carcinoma
|
[61] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[54] | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[55] | |
| Half Maximal Inhibitory Concentration (IC50) | 2000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[44] | |
| Half Maximal Inhibitory Concentration (IC50) | 2000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[45] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2000 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 2000 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
[62] | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
[58] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2009.09 | nM |
RXF 393 cells
|
Renal carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 201.81 | nM |
SK-CO-1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 202.19 | nM |
KYSE-180 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2021.74 | nM |
HT-1197 cells
|
Recurrent bladder carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2023.02 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2027.68 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 203.7 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 2050 | nM |
SGC-7901 cells
|
Gastric carcinoma
|
[49] | |
| Half Maximal Inhibitory Concentration (IC50) | 207.13 | nM |
KGN cells
|
Ovarian granulosa cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 207.22 | nM |
A388 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2081.69 | nM |
SW1463 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2086.84 | nM |
COLO-829 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2086.92 | nM |
DMS 114 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2088.96 | nM |
EFM-19 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 210 | nM |
786-O cells
|
Renal cell carcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[63] | |
| Half Maximal Inhibitory Concentration (IC50) | 211.32 | nM |
NCI-H2030 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 211.8 | nM |
NCI-H727 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21120 | nM |
GES1 cells
|
Normal
|
[34] | |
| Half Maximal Inhibitory Concentration (IC50) | 212.08 | nM |
BC-3 cells
|
Primary effusion lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 215.59 | nM |
CCF-STTG1 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2154.28 | nM |
LN-405 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2155.33 | nM |
UACC-62 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2158.6 | nM |
MDA-MB-134-VI cells
|
Breast lobular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 216.75 | nM |
NMC-G1 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21667.01 | nM |
DK-MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 218.41 | nM |
NCI-H1299 cells (MMAE resistant)
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 219.61 | nM |
RPMI-6666 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2192.54 | nM |
MDA-MB-157 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2199.28 | nM |
COLO-741 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 220.69 | nM |
D283 Med cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 221.16 | nM |
AM-38 cells
|
Glioblastoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2218.2 | nM |
KM12 cells
|
Colon adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 2231.91 | nM |
JEG-3 cells
|
Gestational choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2233.52 | nM |
NB6 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2234.83 | nM |
NCI-H1395 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 224.24 | nM |
LU-99A cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 224.31 | nM |
KYSE-70 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2243.88 | nM |
PC-3 cells
|
Prostate carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 225.16 | nM |
CHL-1 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 225.4 | nM |
CESS cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 225.43 | nM |
A4-Fuk cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 226.18 | nM |
MG-63 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2270 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[64] | |
| Half Maximal Inhibitory Concentration (IC50) | 2271.84 | nM |
KARPAS-45 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2281.19 | nM |
HCC1954 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 229.09 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 229.61 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 22984.02 | nM |
NCI-H1993 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 23 | nM |
Cancer cells
|
Cancer
|
Undisclosed | [29] |
| Half Maximal Inhibitory Concentration (IC50) | 23.32 | nM |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.51 | nM |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.75 | nM |
HT-144 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 230.09 | nM |
MKN-28 cells
|
Gastric epithelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 236.9 | nM |
NCI-H1417 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23698.65 | nM |
U2OS cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2383.11 | nM |
A704 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2389.58 | nM |
SK-N-DZ cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 239.6 | nM |
BCPAP cells
|
Thyroid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2390.59 | nM |
EGI-1 cells
|
Cholangiocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2395.5 | nM |
TALL-1 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2397.77 | nM |
PANC-08-13 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 240.94 | nM |
COR-L23 cells
|
Lung carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2404.36 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 241.42 | nM |
SIMA cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 241.85 | nM |
CAL-62 cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 243.31 | nM |
ARH-77 cells
|
Leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 243.78 | nM |
SF539 cells
|
Gliosarcoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 2435.24 | nM |
NCI-H28 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 244.1 | nM |
COLO-680N cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 245.77 | nM |
T24 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2471.63 | nM |
DMS-79 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2483.42 | nM |
NCI-H889 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 250.63 | nM |
PF-382 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2500 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 25023 | nM |
L02 cells
|
Cervical carcinoma
|
[36] | |
| Half Maximal Inhibitory Concentration (IC50) | 251 | nM |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
[65] | |
| Half Maximal Inhibitory Concentration (IC50) | 251.61 | nM |
NCI-H810 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2545.72 | nM |
Ramos-2G6-4C10 cells
|
Burkitt lymphoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2552.7 | nM |
LXFL 529 cells
|
Non-small cell lung carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 257.09 | nM |
NCI-H1882 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 257.45 | nM |
A101D cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26.19 | nM |
LOUCY cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 260.2 | nM |
NCI-H2126 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 260.82 | nM |
VM-CUB-1 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2623.26 | nM |
BT474-M1 cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 263.7 | nM |
OS-RC-2 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2647.52 | nM |
JVM-3 cells
|
B-cell prolymphocytic leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 266.69 | nM |
LOX IMVI cells
|
Melanoma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 267.92 | nM |
Caki-1 cells
|
Clear cell renal cell carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 270 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 270 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
[53] | |
| Half Maximal Inhibitory Concentration (IC50) | 270 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[51] | |
| Half Maximal Inhibitory Concentration (IC50) | 2703.2 | nM |
NCI-H524 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2716.95 | nM |
SK-MM-2 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 275.45 | nM |
MIA PaCa-2 cells (MSLN expression)
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2750 | nM |
K562-Lucena 1 cells
|
Chronic myelogenous leukemia
|
[66] | |
| Half Maximal Inhibitory Concentration (IC50) | 2750 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[64] | |
| Half Maximal Inhibitory Concentration (IC50) | 2758.03 | nM |
TGW cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 276.13 | nM |
SW837 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 276.26 | nM |
NCI-H358 cells
|
Minimally invasive lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 276.88 | nM |
NCI-H1703 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2785.28 | nM |
Capan-2 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27856.21 | nM |
MKN7 cells
|
Gastric tubular adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2798.98 | nM |
DLD-1 cells
|
Colon adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 2801.93 | nM |
NCI-H82 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 282.57 | nM |
NCI-H1650 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2820.42 | nM |
NCI-H716 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2823.69 | nM |
MSTO-211H cells
|
Pleural biphasic mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 286.22 | nM |
SW626 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 286.23 | nM |
MFE-296 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 286.42 | nM |
SN12C cells
|
Renal cell carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 288.57 | nM |
NCI-H2009 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2886.91 | nM |
COLO-678 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2890 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[64] | |
| Half Maximal Inhibitory Concentration (IC50) | 2898.55 | nM |
AsPC-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.9 | nM |
BPH-1 cells
|
Benign prostatic hyperplasia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 2904.02 | nM |
IGROV-1 cells
|
Ovarian endometrioid adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 2921.43 | nM |
DV-90 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2934.67 | nM |
SNU-387 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2937 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[50] | |
| Half Maximal Inhibitory Concentration (IC50) | 294.34 | nM |
NCI-H2405 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 294.9 | nM |
BL-41 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 295.05 | nM |
SNU-C2B cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 295.8 | nM |
SNB-19 cells
|
Astrocytoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 2982.24 | nM |
KLE cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 299.6 | nM |
no-10 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.524 | nM |
SIG-M5 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.653 | nM |
ES7 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.16 | nM |
LS1034 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.53 | nM |
23132-87 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.61 | nM |
BB30-HNC cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.86 | nM |
CAL-51 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.98 | nM |
ALL-PO cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[46] | |
| Half Maximal Inhibitory Concentration (IC50) | 3000 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[67] | |
| Half Maximal Inhibitory Concentration (IC50) | 3000 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[68] | |
| Half Maximal Inhibitory Concentration (IC50) | 3000 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[68] | |
| Half Maximal Inhibitory Concentration (IC50) | 3000 | nM |
P388 cells
|
Lymphoma
|
[69] | |
| Half Maximal Inhibitory Concentration (IC50) | 301.33 | nM |
A-427 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 303 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[50] | |
| Half Maximal Inhibitory Concentration (IC50) | 303.46 | nM |
SNB-75 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 306.37 | nM |
CTB-1 cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 3069.02 | nM |
OVCAR-3 cells (FZD7 overexpression)
|
Ovarian serous adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 31.93 | nM |
5637 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 311.97 | nM |
BT-20 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3142.84 | nM |
U-118-MG cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3147.35 | nM |
MHH-PREB-1 cells
|
B-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3158.19 | nM |
MDA-MB-175-VII cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 318.23 | nM |
GT3TKB cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 319.14 | nM |
COR-L88 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 319.71 | nM |
Calu-6 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3197.68 | nM |
EB-3 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32.2 | nM |
MCF7-F (fulvestrant resistant) cells
|
Invasive breast carcinoma
|
[37] | |
| Half Maximal Inhibitory Concentration (IC50) | 320.95 | nM |
Calu-3 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 321.6 | nM |
IGR-1 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 321.76 | nM |
LS-411N cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 3221.07 | nM |
Hs 578T cells
|
Invasive breast carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 3222.86 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3235.46 | nM |
NCI-H1522 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3239.64 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32630 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[34] | |
| Half Maximal Inhibitory Concentration (IC50) | 327.79 | nM |
LAN-6 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3279.9 | nM |
NCI-H1092 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 328 | nM |
833K cells
|
Testicular embryonal carcinoma
|
[70] | |
| Half Maximal Inhibitory Concentration (IC50) | 329.56 | nM |
ONS-76 cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3300 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[41] | |
| Half Maximal Inhibitory Concentration (IC50) | 332.56 | nM |
MZ7-mel cells
|
Melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 334.97 | nM |
SK-MEL-5 cells
|
Cutaneous melanoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 3358.35 | nM |
KU-19-19 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 336.08 | nM |
LB647-SCLC cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3362.09 | nM |
SNU-449 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 337.8 | nM |
OE33 cells
|
Barrett adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3381.85 | nM |
CAS-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 34.09 | nM |
KYSE-150 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 34.86 | nM |
RS4
11 cells |
Adult B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 34.96 | nM |
A3-KAW cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3400 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[56] | |
| Half Maximal Inhibitory Concentration (IC50) | 3415.35 | nM |
KP-N-YN cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 342.65 | nM |
NCI-H1770 cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 344.02 | nM |
MS-1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 344.07 | nM |
NCI-H650 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 345.31 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 345.64 | nM |
A-253 cells
|
Submandibular gland squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3457.75 | nM |
P31-FUJ cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3461.27 | nM |
RMG-I cells
|
Ovarian clear cell adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3461.77 | nM |
SN12C cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3484.02 | nM |
HCC1419 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 3491.4 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 35.12 | nM |
NCI-H719 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35.16 | nM |
GI-1 cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35.8 | nM |
HEL cells
|
Erythroleukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35.86 | nM |
TE-8 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 352.5 | nM |
LOX IMVI cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 352.52 | nM |
BB49-HNC cells
|
Floor of mouth squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 353.71 | nM |
HT-1080 cells (FAP expression)
|
Fibrosarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 354 | nM |
U-251MG cells
|
Astrocytoma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 3564.51 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 357.9 | nM |
NB5 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 358.14 | nM |
LK-2 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 36.02 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 364.15 | nM |
KS-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 364.96 | nM |
OE19 cells
|
Esophageal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 365.8 | nM |
UO-31 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3677.75 | nM |
TT cells
|
Thyroid gland medullary carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 371.53 | nM |
HCE-T cells
|
Nornal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 375.23 | nM |
NCI-H1304 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3752.81 | nM |
SW948 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 376968.26 | nM |
A498 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 377.38 | nM |
SKG-IIIa cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 377.46 | nM |
GDM-1 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3787.53 | nM |
SCC-9 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 379.31 | nM |
M14 cells
|
Melanoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 38 | nM |
SF539 cells
|
Gliosarcoma
|
[71] | |
| Half Maximal Inhibitory Concentration (IC50) | 38.58 | nM |
SW1783 cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 38.74 | nM |
CGTH-W-1 cells
|
Thyroid gland squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 380 | nM |
BxPC-3 CDX model cells
|
Pancreatic ductal adenocarcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 380.66 | nM |
CPC-N cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 381.34 | nM |
KYSE-140 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3827.88 | nM |
KMS-12-PE cells
|
Multiple myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3838.07 | nM |
GMS-10 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 387.26 | nM |
SH-4 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 387.62 | nM |
IST-SL2 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 387.7 | nM |
SCC-4 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 389.55 | nM |
OMC-1 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39.4 | nM |
MEL-HO cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39.79 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 392.42 | nM |
Daudi cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3938.8 | nM |
EW-18 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 397.34 | nM |
JVM-2 cells
|
Mantle cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39707.5 | nM |
SK-N-FI cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3974.64 | nM |
SK-MEL-2 cells (MEK inhibitor-resistant)
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39800 | nM |
Farage cells
|
Normal
|
[72] | |
| Half Maximal Inhibitory Concentration (IC50) | 4.368 | nM |
CHP-212 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.787 | nM |
P12-Ichikawa cells
|
T-cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.83 | nM |
HuTu 80 cells
|
Duodenal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.842 | nM |
P30-OHK cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.99 | nM |
NCI-H1651 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[27] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
CH1 cells
|
Ovarian carcinoma
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | 40.11 | nM |
ME-180 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[60] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[73] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
T-47D cells
|
Invasive breast carcinoma
|
[53] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
V79 cells
|
Normal
|
[74] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[47] | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[48] | |
| Half Maximal Inhibitory Concentration (IC50) | 402.82 | nM |
NCI-H510A cells
|
Lung small cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 403.65 | nM |
786-O cells
|
Renal cell carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 4030 | nM |
Peripheral blood mononuclear cells
|
Normal
|
Undisclosed | [66] |
| Half Maximal Inhibitory Concentration (IC50) | 404.19 | nM |
NCI-H1838 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4071.59 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 41.18 | nM |
CAL-27 cells
|
Tongue adenosquamous carcinom
|
||
| Half Maximal Inhibitory Concentration (IC50) | 410 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[50] | |
| Half Maximal Inhibitory Concentration (IC50) | 410.99 | nM |
GCIY cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 411.59 | nM |
NCI-H747 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4146.21 | nM |
IST-MES1 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 415.28 | nM |
NCI-H1694 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 418.01 | nM |
UACC-893 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4194.46 | nM |
PLC-PRF-5 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 421.7 | nM |
DMS 114 cells
|
Lung small cell carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 425.26 | nM |
DMS-153 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 428.21 | nM |
GAMG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 429.62 | nM |
LB373-MEL-D cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 429.83 | nM |
8505C cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 429.95 | nM |
DB cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43.77 | nM |
A-431 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 430 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 430.68 | nM |
LoVo cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 432.47 | nM |
MZ2-MEL cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 434.17 | nM |
L-363 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 434.45 | nM |
HSC-4 cells
|
Cervical lymph node
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4367.51 | nM |
YAPC cells
|
Pancreas carincoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 438.12 | nM |
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 438758 | nM |
SW780 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4389.75 | nM |
RXF 393 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 439.29 | nM |
SK-LMS-1 cells
|
Vulvar leiomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 44.91 | nM |
SW 954 cells
|
Vulva squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 440 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[64] | |
| Half Maximal Inhibitory Concentration (IC50) | 440.64 | nM |
HO-1-N-1 cells
|
Buccal mucosa squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 440.65 | nM |
OAW-28 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4400 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[32] | |
| Half Maximal Inhibitory Concentration (IC50) | 447.7 | nM |
SBC-1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 447.71 | nM |
SNB-75 cells
|
Glioblastoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 450 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[75] | |
| Half Maximal Inhibitory Concentration (IC50) | 450 | nM |
Daudi cells
|
Burkitt lymphoma
|
[66] | |
| Half Maximal Inhibitory Concentration (IC50) | 450.08 | nM |
LNCaP-Clone-FGC cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 450.11 | nM |
MZ1-PC cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 452.18 | nM |
GB-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4559.67 | nM |
LP-1 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4563.84 | nM |
JAR cells
|
Gestational choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 46.49 | nM |
CAL-39 cells
|
Vulvar squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 46.72 | nM |
LU-134-A cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 460 | nM |
GM00637 cells
|
Normal
|
[51] | |
| Half Maximal Inhibitory Concentration (IC50) | 460.87 | nM |
LCLC-103H cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4604.7 | nM |
GCT cells
|
Pleomorphic sarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 4623.81 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 463.33 | nM |
YT cells
|
Natural killer cell lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 464.62 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4668.27 | nM |
SW1088 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 46733.86 | nM |
CAL-72 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 468.78 | nM |
CaR-1 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 47.47 | nM |
DU-4475 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 470 | nM |
K-562 cells
|
Chronic myelogenous leukemia
|
[66] | |
| Half Maximal Inhibitory Concentration (IC50) | 470 | nM |
M14 cells
|
Melanoma
|
[71] | |
| Half Maximal Inhibitory Concentration (IC50) | 4731.93 | nM |
NCI-H345 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 474.31 | nM |
SK-MEL-30 cells
|
Cutaneous melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 4742.42 | nM |
NCI-ADR-RES cells
|
High grade ovarian serous adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 48 | nM |
P388/S cells
|
Leukemia
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 48.39 | nM |
DEL/BVR cells
|
Anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4807.2 | nM |
Calu-1 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 481.7 | nM |
TCCSUP cells
|
Bladder carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 485.29 | nM |
SW620 cells
|
Colon adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 486.87 | nM |
C-33-A cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 4864.07 | nM |
TK-10 cells
|
Renal carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 487.11 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 49.29 | nM |
HGC-27 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 49.57 | nM |
RH-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 490.91 | nM |
SF268 cells
|
Astrocytoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 491.25 | nM |
CAL-12T cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 491.27 | nM |
PC-14 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 494.36 | nM |
ST486 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 498.32 | nM |
HLE cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.545 | nM |
COR-L279 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.827 | nM |
CMK cells
|
Down syndrome
|
||
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[70] | |
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | 50.8 | nM |
P388 cells
|
Lymphoma
|
[37] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
[71] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
PC-3 cells
|
Prostate carcinoma
|
[77] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
HCT 116 cells
|
Colon carcinoma
|
[78] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[79] | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
THP-1 cells
|
Childhood acute monocytic leukemia
|
[61] | |
| Half Maximal Inhibitory Concentration (IC50) | 500.49 | nM |
TE-9 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 500.96 | nM |
AU565 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5070.36 | nM |
ECC4 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 51.12 | nM |
SK-MES-1 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 51.25 | nM |
MEL-JUSO cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 513.11 | nM |
LU-165 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 513.36 | nM |
EW-11 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5155.1 | nM |
DOK cells
|
Oral epithelial dysplasia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 517.22 | nM |
FTC-133 cells
|
Thyroid gland follicular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 52.16 | nM |
VA-ES-BJ cells
|
Epithelioid sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 52.51 | nM |
EW-13 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 520 | nM |
HeLa S3 cells
|
Endocervical adenocarcinoma
|
[57] | |
| Half Maximal Inhibitory Concentration (IC50) | 523.01 | nM |
NCI-H1648 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 523.28 | nM |
AN3-CA cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 523.44 | nM |
KURAMOCHI cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 523.75 | nM |
T98G cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 528.32 | nM |
TK-10 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53.75 | nM |
Ca-Ski cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 534.56 | nM |
LB2518-MEL cells
|
Melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 5345.64 | nM |
SNB-78 cells
|
Glioblastoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 535 | nM |
P388/ADR cells
|
Lymphoma
|
[76] | |
| Half Maximal Inhibitory Concentration (IC50) | 536.53 | nM |
CAL-33 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 537.52 | nM |
A-172 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 540 | nM |
SF-295 cells
|
Glioblastoma
|
[71] | |
| Half Maximal Inhibitory Concentration (IC50) | 540.04 | nM |
D-263MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 540.59 | nM |
CAMA-1 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 540.81 | nM |
MKN-1 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5400 | nM |
Hep-G2 cells
|
Hepatoblastoma
|
[42] | |
| Half Maximal Inhibitory Concentration (IC50) | 5400 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
[41] | |
| Half Maximal Inhibitory Concentration (IC50) | 541.58 | nM |
NCI-H661 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5436.57 | nM |
RL cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5436.94 | nM |
NCI-H1755 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 545 | nM |
YKG-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 55.37 | nM |
LXF-289 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 550 | nM |
HCT 116 cells
|
Colon carcinoma
|
[64] | |
| Half Maximal Inhibitory Concentration (IC50) | 553.71 | nM |
GOTO cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 56.22 | nM |
IM-9 cells
|
Multiple myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 560 | nM |
HCT 116 cells
|
Colon carcinoma
|
[54] | |
| Half Maximal Inhibitory Concentration (IC50) | 560 | nM |
HCT 116 cells
|
Colon carcinoma
|
[55] | |
| Half Maximal Inhibitory Concentration (IC50) | 5600 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
[56] | |
| Half Maximal Inhibitory Concentration (IC50) | 563.11 | nM |
KYSE-450 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 567.01 | nM |
UMC-11 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 57.94 | nM |
HCE-4 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 570.26 | nM |
DBTRG-05MG cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 5714.79 | nM |
MDA-MB-231 cells (5T4 overexpression)
|
Breast adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 578 | nM |
Jurkat cells
|
T acute lymphoblastic leukemia
|
[50] | |
| Half Maximal Inhibitory Concentration (IC50) | 5789.44 | nM |
HTC-C3 cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 58.73 | nM |
TYK-nu cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 580 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
[71] | |
| Half Maximal Inhibitory Concentration (IC50) | 5800 | nM |
Caco-2 cells
|
Colon adenocarcinoma
|
[30] | |
| Half Maximal Inhibitory Concentration (IC50) | 583.59 | nM |
KYSE-410 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 585.19 | nM |
MOLT-16 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 588.82 | nM |
HCC2218 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5883.51 | nM |
PFSK-1 cells
|
Primitive neuroectodermal tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 59.54 | nM |
NCI-H748 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 590 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[18] | |
| Half Maximal Inhibitory Concentration (IC50) | 591.14 | nM |
EFO-21 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 592.44 | nM |
S-117 cells
|
Thyroid gland sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 593.82 | nM |
HCC1937 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 595.5 | nM |
THP-1 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 596.24 | nM |
GAK cells
|
Vulvar melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 596.91 | nM |
SW756 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5963.51 | nM |
CAL-120 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 597.14 | nM |
KG-1 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.06 | nM |
MHH-CALL-2 cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.067 | nM |
BV-173 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.168 | nM |
NCI-H209 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.452 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.519 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
A2780 cisR cells
|
Cisplatin-resistant ovarian carcinoma
|
[59] | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
[46] | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[46] | |
| Half Maximal Inhibitory Concentration (IC50) | 601.65 | nM |
D-542MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 604.11 | nM |
HCC38 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 61.2 | nM |
ABC-1 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 61.68 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 61.95 | nM |
EW-3 cells
|
Ewing sarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 613.76 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 613.76 | nM |
M19-MEL cells
|
Melanoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 614.65 | nM |
SAS cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 62.51 | nM |
NCI-H2342 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6203.02 | nM |
Hs 578T cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6249.4 | nM |
DG-75 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 629.17 | nM |
RVH-421 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 629.54 | nM |
JIYOYE cells
|
Burkitts lymhoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 63.76 | nM |
SK-PN-DW cells
|
Primitive neuroectodermal tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 630 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[54] | |
| Half Maximal Inhibitory Concentration (IC50) | 630 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[55] | |
| Half Maximal Inhibitory Concentration (IC50) | 6323.64 | nM |
NCI-H2227 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 634.47 | nM |
G-401 cells
|
Kidney Wilm's tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6348.57 | nM |
OPM-2 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 637.05 | nM |
SW1990 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6371.91 | nM |
T-47D cells
|
Invasive breast carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 64 | nM |
Cancer cells
|
Cancer
|
Undisclosed | [29] |
| Half Maximal Inhibitory Concentration (IC50) | 640.12 | nM |
KP-N-YS cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 640.25 | nM |
HD-MY-Z cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 641.66 | nM |
LAMA-84 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 642.49 | nM |
SW13 cells
|
Adrenal cortex carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 644.61 | nM |
HCC1569 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 644.95 | nM |
CP66-MEL cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 645.66 | nM |
SK-HEP1 cells
|
Hepatoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6454.52 | nM |
HuO-3N1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 646.03 | nM |
NB13 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 65.36 | nM |
EB2 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 65.88 | nM |
CAL-85-1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 657.39 | nM |
NY cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 66 | nM |
HuT 78 cells
|
T lymphocytic leukemia
|
[50] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 666.81 | nM |
NCI-H522 cells
|
Non-small cell lung carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 6684.51 | nM |
D-392MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 67.37 | nM |
NCI-H526 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 672.13 | nM |
EHEB cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6743.09 | nM |
SNU-16 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 68 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[80] | |
| Half Maximal Inhibitory Concentration (IC50) | 683.36 | nM |
MEG-01 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 694.33 | nM |
HCC70 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 696.91 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 697.34 | nM |
NCI-H1792 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 698.24 | nM |
HEC-1 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
SW480 cells
|
Colon adenocarcinoma
|
[25] | |
| Half Maximal Inhibitory Concentration (IC50) | 7.112 | nM |
769-P cells
|
Renal cell carcinom
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.288 | nM |
ES1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.545 | nM |
COLO-668 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.831 | nM |
NKM-1 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.882 | nM |
ES3 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
HCT 15 cells
|
Colon adenocarcinoma
|
[53] | |
| Half Maximal Inhibitory Concentration (IC50) | 70.61 | nM |
MFH-ino cells
|
Pleomorphic sarcoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 701.46 | nM |
HCT 116 cells
|
Colon carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 707.99 | nM |
NCI-H187 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7099 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[36] | |
| Half Maximal Inhibitory Concentration (IC50) | 710 | nM |
TGBC24TKB cells
|
Gallbladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 710.55 | nM |
HuP-T3 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 711.12 | nM |
SK-MEL3 cells
|
Melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 714.5 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
[31] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 714.5 | nM |
A498 cells
|
Renal carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 72.08 | nM |
ACHN cells
|
Renal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 72.35 | nM |
MONO-MAC-6 cells
|
Acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 72.44 | nM |
CHP-126 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 72.58 | nM |
SW1710 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 72.6 | nM |
TE-10 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 723.95 | nM |
MDA-MB-415 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 726.85 | nM |
HCC2157 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 73.7 | nM |
TE-15 cells
|
Esophageal squamous cell carcinom
|
||
| Half Maximal Inhibitory Concentration (IC50) | 73.75 | nM |
Panc1005 cells
|
Pancreatic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 740.57 | nM |
NCI-H2081 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 745.62 | nM |
ES6 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 75.28 | nM |
BHY cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 75.54 | nM |
HSC-3 cells
|
Oral squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 758.58 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 77.33 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 772.18 | nM |
KYSE-520 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7727.58 | nM |
CW-2 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 774.78 | nM |
BxPC-3 CDX model cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7742.02 | nM |
no-11 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 777.21 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 779.74 | nM |
LB771-HNC cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 78.66 | nM |
COLO-800 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 780.03 | nM |
CP50-MEL-B cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 782.54 | nM |
HN cells
|
Cervical lymph node
|
||
| Half Maximal Inhibitory Concentration (IC50) | 782.97 | nM |
EW-24 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 789.6 | nM |
A673 cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 790 | nM |
SW480 cells
|
Colon adenocarcinoma
|
[64] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 796.16 | nM |
Malme-3M cells
|
Melanoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 799.3 | nM |
COLO-684 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.519 | nM |
SCC-3 cells
|
B-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.609 | nM |
SU-DHL-1 cells
|
Anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.781 | nM |
ML-2 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 80 | nM |
A-549 cells
|
Lung adenocarcinoma
|
[28] | |
| Half Maximal Inhibitory Concentration (IC50) | 800 | nM |
V79 cells
|
Normal
|
[74] | |
| Half Maximal Inhibitory Concentration (IC50) | 808.56 | nM |
DMS-53 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 808.98 | nM |
MDA-MB-361 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 81.65 | nM |
NB10 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 810 | nM |
HeLa cells
|
Endocervical adenocarcinoma
|
[81] | |
| Half Maximal Inhibitory Concentration (IC50) | 8127.2 | nM |
SNU-C1 cells
|
Colon adenocarcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 813.14 | nM |
SNU-475 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 816.08 | nM |
LB831-BLC cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 82.8 | nM |
SK-UT-1 cells
|
Uterine corpus leiomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 83 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
[82] | |
| Half Maximal Inhibitory Concentration (IC50) | 83.42 | nM |
HSC-2 cells
|
Oral cavity squamous cell carcinoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 831.76 | nM |
Tumor cells
|
Tumour
|
Undisclosed | [83] |
| Half Maximal Inhibitory Concentration (IC50) | 8348.73 | nM |
MFE-280 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 84 | nM |
GP5d cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 84.19 | nM |
A204 cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 84237.74 | nM |
WM-115 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8450 | nM |
U2OS cells
|
Osteosarcoma
|
[64] | |
| Half Maximal Inhibitory Concentration (IC50) | 847.28 | nM |
RCM-1 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 84724.26 | nM |
D-502MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 849.97 | nM |
NCI-H2347 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 85.27 | nM |
BFTC-909 cells
|
Renal pelvis urothelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 85.69 | nM |
NCI-H2087 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 85.92 | nM |
G-402 cells
|
Kidney neoplasm
|
||
| Half Maximal Inhibitory Concentration (IC50) | 852.81 | nM |
NCI-H2141 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8611.64 | nM |
KINGS-1 cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 862.32 | nM |
Becker cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 862.33 | nM |
LC-1F cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 863.86 | nM |
SCC-15 cells
|
Squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 866.18 | nM |
U266B1 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 87.39 | nM |
647-V cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 870.36 | nM |
SCC-25 cells
|
Squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 873.36 | nM |
NCI-H1155 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 88.01 | nM |
Daoy cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 88.07 | nM |
EW-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 88.81 | nM |
BC1 cells
|
Primary effusion lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 884.41 | nM |
NCI-H292 cells
|
Lung mucoepidermoid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 886 | nM |
NCI-H2196 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 89.42 | nM |
OAW-42 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8921.3 | nM |
HCC1187 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 893 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 893.67 | nM |
TE-6 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8936.28 | nM |
NCI-H2452 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 899.63 | nM |
NCI-H1693 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 90.25 | nM |
COLO-679 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 900 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[63] | |
| Half Maximal Inhibitory Concentration (IC50) | 900 | nM |
GM00637 cells
|
Normal
|
[84] | |
| Half Maximal Inhibitory Concentration (IC50) | 903.51 | nM |
HuCCT-1 cells
|
Liver bile duct carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 906.74 | nM |
NCI-H1581 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 907.39 | nM |
Karpas-422 cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 91.77 | nM |
TE-11 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 92.69 | nM |
BFTC-905 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9284 | nM |
C2BBe1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 93.15 | nM |
KP-4 cells
|
Pancreatic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 93.83 | nM |
DoHH2 CDX model cells
|
Diffuse large B-cell lymphoma germinal center B-cell type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 932.32 | nM |
C8166 cells
|
Leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 935.16 | nM |
BEN cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 95.14 | nM |
L-540 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 95.72 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 9552.33 | nM |
MeWo cells
|
Melanoma
|
||
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 959.4 | nM |
SN12K1 cells
|
Lung metastasis of renal carcinoma
|
[31] | |
| Half Maximal Inhibitory Concentration (IC50) | 96.53 | nM |
DSH1 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 963.03 | nM |
SCLC-21H cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 967.11 | nM |
HT-1376 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 974.37 | nM |
NCI-H1963 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 99 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
[69] | |
| Half Maximal Inhibitory Concentration (IC50) | 991.22 | nM |
MPP-89 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 993 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[70] | |
| Half Maximal Cell Growth Inhibitory Concentration (GI50) | 995.41 | nM |
NCI-H322M cells
|
Minimally invasive lung adenocarcinoma
|
[31] | |
| Half Maximal Effective Concentration (EC50) | 0.001 | uM |
EMT6 cells
|
Mammary gland malignant neoplasms
|
[85] | |
| Half Maximal Effective Concentration (EC50) | 0.18 | uM |
WiDr cells
|
Colon adenocarcinoma
|
[86] | |
| Half Maximal Effective Concentration (EC50) | 0.21 | uM |
Daoy cells
|
Medulloblastoma
|
[86] | |
| Half Maximal Effective Concentration (EC50) | 0.7 | uM |
EMT6 cells
|
Mammary gland malignant neoplasms
|
[85] | |
| Half Maximal Effective Concentration (EC50) | 19.1 | uM |
NUGC-4 cells
|
Gastric signet ring cell adenocarcinoma
|
[87] | |
| Half Maximal Effective Concentration (EC50) | 20.2 | uM |
SCL-I cells
|
Skin squamous cell carcinoma
|
[87] | |
| Half Maximal Effective Concentration (EC50) | 20.7 | uM |
L6 cells
|
Normal
|
[87] | |
| Half Maximal Effective Concentration (EC50) | 49 | uM |
KATO III cells
|
Down syndrome
|
[87] |
Each Antibody-drug Conjugate Related to This Payload
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.